ESR1 and breast carcinoma: CDK4/6 inhibitors (CDK4/6i) now play a key role in the treatment of advanced, estrogen receptor–positive (ER+) breast cancers (1), with established efficacy in combination with endocrine therapy in both first- and second-line treatment (2–8).